Oralair

Allergen extract from grass pollen (Dactylis glomerata, Anthoxanthum odoratum, Lolium perenne, Poa pratensis), the active ingredient in Oralair, is a allergen immunotherapy presented as a sublingual tablet for sublingual use. It treats seasonal allergic rhinitis and allergic conjunctivitis caused by grass pollen in patients with confirmed sensitivity.

GNH USA supplies Oralair as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Oralair is an allergen immunotherapy indicated for grass‑pollen related allergic conditions, helping modify the underlying allergic response. - Seasonal allergic rhinitis: reduces nasal congestion, sneezing and itching during grass pollen season. - Allergic conjunctivitis: alleviates eye redness, tearing and itching associated with grass pollen exposure. - Long‑term disease modification: may decrease the need for symptomatic medication over multiple pollen seasons.

Adverse reactions to Oralair are generally mild to moderate and reflect local immune activation in the mouth and throat.

Common Side Effects: - Oral itching or tingling: mild discomfort in the mouth shortly after tablet placement. - Throat irritation: transient soreness or scratchy feeling. - Mild gastrointestinal upset: occasional nausea or abdominal discomfort. - Localized swelling of the lips or tongue: transient and self‑limited. - Headache: mild and short‑lived. - Upper respiratory symptoms: mild cough or nasal congestion.

Serious or Rare Side Effects: - Anaphylaxis: severe, systemic allergic reaction requiring immediate medical attention. - Angio‑edema of the face or airway: rapid swelling that can compromise breathing. - Severe bronchospasm: sudden difficulty breathing or wheezing. - Persistent gastrointestinal bleeding: uncommon but serious gastrointestinal upset. - Systemic urticaria: widespread hives beyond the oral cavity. - Cardiovascular collapse: rare life‑threatening drop in blood pressure.

Before initiating Oralair, clinicians should evaluate patient history and comorbid conditions. - Contraindication: known severe reaction to any component of the tablet. - Caution in uncontrolled asthma: assess respiratory status before starting therapy. - Monitor during first administration: observe for at least 30 minutes for systemic reactions. - Avoid use with beta‑blockers: may mask treatment of anaphylaxis. - Pregnancy and lactation: prescribe only if benefit outweighs potential risk. - Store at ambient temperature: keep below 25°C, retain original packaging, protect from moisture and direct sunlight.

Oralair has a limited interaction profile, but certain medications may influence its safety or efficacy.

Major Interactions (Avoid): - Beta‑blockers: may reduce effectiveness of emergency epinephrine treatment for anaphylaxis. - ACE inhibitors: potential to exacerbate angio‑edema if an allergic reaction occurs.

Moderate Interactions (Monitor Closely): - Antihistamines: may blunt assessment of local oral reactions during dose escalation.\n- Corticosteroids: concurrent systemic use may mask early signs of an allergic response. - Immunosuppressants: could alter the immunologic response to the allergen extract.